Cellectis S.A. (NASDAQ:CLLS) Receives $6.33 Average PT from Analysts

Shares of Cellectis S.A. (NASDAQ:CLLS) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $6.3333.

CLLS has been the topic of several recent research reports. Clear Str upgraded shares of Cellectis to a “strong-buy” rating in a report on Tuesday, December 23rd. Jefferies Financial Group assumed coverage on shares of Cellectis in a research note on Tuesday. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, January 21st.

Institutional Trading of Cellectis

Several large investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new position in Cellectis in the fourth quarter worth about $34,000. Millennium Management LLC raised its position in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. Delaney Dennis R acquired a new position in Cellectis in the third quarter worth $68,000. B Group Inc. lifted its position in Cellectis by 0.8% during the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after buying an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Cellectis during the 3rd quarter worth $72,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Stock Down 1.7%

NASDAQ CLLS opened at $3.99 on Tuesday. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.63. Cellectis has a 1-year low of $1.10 and a 1-year high of $5.48. The business has a 50 day moving average price of $4.22 and a 200 day moving average price of $3.78.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.